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J.P. Clancy1, G. Spencer-Green2, for the VX-809–101 Study Group. 1University
of Alabama at Birmingham, Birmingham, AL, USA; 2Vertex Pharmaceuticals,
Cambridge, MA, USA
The predominant CF-causing mutation, F508del, results in defective folding of the
cystic ﬁbrosis transmembrane conductance regulator (CFTR) protein. Restoration
of CFTR ion transport function is a novel therapeutic strategy under investigation
in CF. The current randomized, double-blind, placebo-controlled trial evaluated
the safety and tolerability of four doses of VX-809, an orally bioavailable in-
vestigational F508del-CFTR corrector, in CF adults homozygous for F508del–
CFTR. Participants were randomized to 28 days of once-daily VX-809 at doses
of 25 (n = 18), 50 (n = 18), 100 (n = 17), or 200mg (n = 19) or placebo (n = 17).
Secondary endpoints included biomarkers of CFTR function (sweat chloride and
nasal potential difference [NPD]), pulmonary function (FEV1), and patient-reported
outcomes (CFQ-R). Exploratory assessment of F508del-CFTR maturation in rectal
tissue (B- to C-band conversion) was also included. VX-809 was well-tolerated
across the dose groups. Sweat chloride reductions were seen as early as Day 7,
and at Day 28 there was a clear dose response to VX-809 in mean sweat chloride
change from baseline (p = 0.0013). Treatment differences vs placebo for VX-809
100mg (−6.1mmol/L [95%CI: −12.2, −0.01]) and 200mg groups (−8.2mmol/L
[−14.3, −2.1]) were statistically signiﬁcant (p = 0.05 and p< 0.01, respectively). No
signiﬁcant differences from baseline were observed for VX-809 in mean NPD zero
chloride plus isoproterenol response, FEV1, or CFQ-R. No B- to C-band conversion
was detected in rectal tissue for any VX-809 dose group. In conclusion, VX-809 was
well-tolerated at all doses tested and showed statistically signiﬁcant improvement in
sweat chloride concentrations at higher doses, suggesting an increase in F508del-
CFTR activity in patients during dosing. These results support future evaluation of
VX-809, likely in combination with the CFTR potentiator, VX-770, as a potential
treatment strategy for CF patients with the F508del-CFTR mutation.
Sponsored by Vertex Pharmaceuticals with support from Cystic Fibrosis Foundation
Therapeutics.
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VX-770 is an investigational potentiator of CFTR, which is the defective ion
channel causative of CF. We previously reported safety and efﬁcacy results from a
randomized, double-blind, placebo-controlled phase 2 trial of VX-770 in 39 CF
subjects with G551D-CFTR. Secondary analyses demonstrated that at 14 days
there was a signiﬁcant improvement in Cl− conductance by NPD (DLowCl+Iso)
at the 150mg dose (mean −4.6mV; p< 0.01 within-subject, p< 0.05 vs placebo;
n = 16). Reduced hyperabsorption of Na+, reﬂected by an increase in Ringer’s
PD (mean 16.1mV; p< 0.05 within-subject and vs placebo) was also observed,
suggesting CFTR functional improvements were accompanied by reduced ENaC
activity. These results were predicted based on the in vitro pharmacology of VX-
770 where, in forskolin-stimulated primary F508del/G551D-HBE, VX-770 (10 mM)
improved Cl− transport (mean 4.3mV). Similarly, addition of VX-770 prior to
amiloride decreased PD (mean 21.9mV), reﬂecting reduced Na+ hyperabsorption.
The change in Cl− conductance of F508del/G551D-HBE in vitro (to ~50% wild-
type activity) paralleled the change in Cl− conductance clinically measured by
NPD (for the 150mg group, mean 29.7% of normal historical controls obtained in
a multicenter dataset [N=16] during the same time period, p< 0.0001 vs baseline
7.8%). Similarities in ion transport response to VX-770 in HBE in vitro and NPD
measured in patients suggest that HBE is a useful model for testing the modulation
of CFTR using novel compounds.
Study sponsored by Vertex Pharmaceuticals Incorporated with support from Cystic
Fibrosis Foundation Therapeutics Inc.and US FDA Ofﬁce of Orphan Products
Development.
75 Oral miglustat in homozygous F508del CF patients
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In vitro and in vivo preclinical studies have shown that miglustat, a drug marketed
for type 1 Gaucher disease and Niemann-Pick type C disease (NP-C), may represent
a potential therapy for CF. This Phase IIa double-blind, randomized, placebo-
controlled, 2-period/2-treatment crossover study aimed at evaluating the effect of
miglustat on NPD and its pharmacokinetics in homozygous F508del CF patients.
Eleven patients (26.3±7.7 y) were enrolled in one center, and were assessed in two
8-day cycles of oral placebo or miglustat 200mg t.i.d. separated by a 14-day washout
period. The primary endpoint was the change from baseline to Day 8 of Total
Chloride Secretion (TCS). No exclusion criteria were set based on residual chloride
conductance before treatment. All patients completed the study. The reproducibility
of baseline NPD measurements was lower than considered when powering the
study. Several patients had a TCS>−5mV at baseline indicating unexpected normal
chloride transport. No statistically signiﬁcant changes were detected for TCS. There
were no serious adverse events. Pharmacokinetic data were similar to those in NP-C
patients receiving the same dosage regimen. Due to the inclusion of CF patients
with residual chloride secretion at baseline and lower than expected reproducibility
of NPD measurements, no conclusion can be drawn about the impact of miglustat
on TCS. Further studies are warranted.
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Background: Pts with CF are vulnerable to declines in FEV1 during adolescence
and need therapies that delay/reduce lung function loss. Denufosol tetrasodium is a
novel ion channel regulator under development that enhances mucociliary clearance
and hydration in CF pts regardless of CFTR defect by increasing Cl− secretion,
inhibiting Na+ absorption and stimulating ciliary beat frequency.
Methods: We examined efﬁcacy and safety data from an adolescent subgroup
(12−18 yo; n = 123) from a Phase 3, placebo (Pl)-controlled trial (TIGER-1) in
pts 5 yrs with FEV1 75% pred. on US standard of care. The study was a 24-wk
double-blind phase with a 24-wk denufosol-only open label extension (OLE).
Results: In the intent-to-treat population (n = 352), denufosol treatment led to an
absolute FEV1 change from baseline to Week 24 endpoint (Wk24E) of 45mL
[(+2%); p = 0.047] compared to Pl. In adolescents, the change in FEV1 from
baseline to Wk24E for denufosol was +112mL (+4.0%; n = 59) compared to −10ml
(−0.6%; n = 64) for Pl (p = 0.013). In terms of % pred FEV1, a change from baseline
to Wk24E of −1.1% was observed in denufosol vs −4.1% in Pl (p = 0.055). In
the OLE, for adolescent pts on denufosol the change from baseline in FEV1 was
+226mL (+8.8%, −0.9% predicted) at Wk 48, whereas pts who switched from Pl to
denufosol at Wk 24 had a change over 48 wks of +83mL (+3.4%) and a stabilized
decline in % pred FEV1 (−4.5% at Wk 48).
Conclusion: Denufosol in adolescent pts provided signiﬁcant improvements in lung
function on top of standard care. These results point to the potential utility of
denufosol in ameliorating the accelerated loss of lung function during adolescence.
